What is Proscia?
Proscia is a software company dedicated to the digital transformation of pathology. By providing the Concentriq digital pathology platform and a suite of powerful AI applications, the company enables laboratories and health systems to unlock new insights from tissue samples. This technological shift is essential for modernizing clinical workflows, accelerating drug discovery, and fulfilling the promise of precision care. Proscia operates at the intersection of health tech and enterprise software, positioning itself as an indispensable partner for institutions seeking to integrate advanced computational tools into their diagnostic processes.
How much funding has Proscia raised?
Proscia has raised a total of $129.6M across 7 funding rounds:
Angel/Seed
$1M
Private Equity
$927K
Series A
$8.3M
Debt
$350K
Series B
$23M
Series C
$46M
Other Financing Round
$50M
Angel/Seed (2016): $1M with participation from Robin Hood Ventures, TCP Venture Capital, Emerald Development Managers, and A-Level Capital
Private Equity (2017): $927K, investors not publicly disclosed
Series A (2018): $8.3M supported by Flybridge Capital Partners
Debt (2020): $350K featuring PPP
Series B (2020): $23M backed by Hitachi Ventures and BA Venture Partners
Series C (2024): $46M with participation from Alpha Intelligence Capital, Hitachi Ventures, Highline Capital Management, Triangle Peak Partners, and Scale Venture Partners
Other Financing Round (2025): $50M led by Emerald Development Managers, Razor's Edge Management, AI Capital Partners, Fusion Fund, Interwoven Ventures, Triangle Peak Partners, Insight Partners, and GPG Advisers
Key Investors in Proscia
Insight Partners
A global venture capital and private equity firm that invests in high-growth software and technology companies, providing hands-on operational support to help businesses scale from early stage to IPO.
Hitachi Ventures
The corporate venture arm of Hitachi, focusing on world-changing innovations across digital, industrial, environmental, and healthcare sectors by blending global power with startup agility.
Scale Venture Partners
An early-stage venture capital firm that invests in category-defining businesses, offering hands-on consulting and go-to-market advisory to support companies through scalable growth.
What's next for Proscia?
With the infusion of $50M, Proscia is poised to deepen its investment in AI-driven diagnostic capabilities and expand its market footprint. The strategic focus will likely center on scaling the deployment of its software infrastructure to meet the increasing demand for digitized pathology workflows. As the company moves into this next phase of maturity, it will continue to leverage its strong network of investors to navigate the complexities of the global healthcare market, ensuring that its platform remains at the forefront of clinical innovation and operational efficiency.
See full Proscia company page
